Please login to the form below

A uniquely English genomic medicine service

The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.

pwire_blog_genome.jpg?nc=1564148345

In November, Matt Hancock, the UK Secretary of State for Health and Social Care, announced the next stage of the government’s plan for genomic medicine in the UK. He revealed his ambition to reach 5,000,000 genomic analyses across the country. Importantly, the plan called for genomic sequencing to be embedded across the nation as a standard offering for patients.

His speech marked the next phase of a project, which began in 2013 with the formation of Genomics England. The company was set the task of sequencing 100,000 genomes, and last year it reached its target, leaving behind a legacy of data for the National Health Service (NHS).

Now, Hancock has tasked the team with embedding these processes on a far wider scale and sustainably rolling out whole genome sequencing across the nation. This means developing agile processes and platforms that can respond to new discoveries at rapid speed.

Blue Latitude Health sat down with Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the organisation is ensuring every patient has access to genomic medicine.

A nationalised system

During the last 15 years, the NHS has been quietly considering how to respond and adapt to precision medicine. The egalitarian nature of the nationalised service places great weight on establishing how new innovations can meet the needs of every patient, while ensuring precision medicine is free at the point of delivery.

This means the UK is uniquely positioned to develop a uniform approach to embedding precision medicine through a single system in which new processes and technologies can be rolled out. As a result, the NHS never questioned whether precision medicines will be accessible for the masses. Instead, it is focusing on how to make that a reality.

Dr Tom Fowler has played a core role in implementing genomic medicine in the UK. As Director of Public Health at Genomics England, he led the rare disease pilot phase of the 100,000 Genomes Project. Now he’s helping to make genomic medicine an ordinary part of patient care.

“What we’re doing is cutting edge,” he explains. “It means moving from a single project to building a new standardised service – a whole series of exciting things come along with that. We have to think about novel ways of working with very new information.”

“One of the big challenges is building the relevant structures and systems to make this work, as well as embedding the platforms. There are always going to be challenges around developing a national system, but that’s also why this endeavour is so interesting.”

Ending the diagnostic odyssey

To prepare England for precision medicine, the NHS is rolling out a genomic medicine service to give patients who have not benefitted from standard clinical tests access to whole genome sequencing.

The hope is that this will prevent patients from becoming trapped in a ‘diagnostic odyssey’, in which they attend numerous doctor’s appointments and have many tests before receiving a diagnosis. This process can take years, but Genomics England believes whole genome sequencing could provide much faster results.

Helping these patients will mean carrying out whole genome sequencing upfront, before other genetic tests are conducted. However, the human genome consists of 2.9 billion base pairs, equating to 752 megabytes of data per person. Much of this data is uninterpretable and needs to be compared with clinical information and other genomic data for insights to be captured.

Adding to the complexity, new discoveries are being made at a rapid speed and this research needs to be fed back into the knowledge base of testing to ensure the findings benefit other patients. As a result, the service has to be responsive to technological and scientific advancements.

“As new knowledge is generated, we can identify rare variants,” says Tom. “This information has to be returned to the NHS Genomic Medicine Centres. That’s why we’re very careful to say we don’t return reports. Instead, we return results of genomic analysis, which are then clinically interpreted by the NHS and the most appropriate accredited laboratories.”

These virtual panels are designed to foster consensus across the scientific community. It’s important for clinicians to prioritise the information found during whole genome sequencing, so they can sift through the vast amounts of data to find subtle variations.

The genomic data included in the virtual panels come from a variety of sources and each gene has been reviewed and appraised by experts using a traffic light system. For example, if there is sufficient evidence for a gene causing a disorder, it is ranked green; if we are awaiting further evidence for a potentially promising gene it is rated amber, and genes considered to have insufficient evidence are rated red. If a gene is highly ranked it can be confidently included in the panel.

“We all acknowledge the challenge of keeping up with the knowledge in this particular space. One of the key advantages of having virtual panels is that when you have to adapt and change, you can do it in a virtual sense rather than a physical sense. It makes it more efficient and much easier to keep up with those changes,” Tom explains.

DOWNLOAD THE FULL ARTICLE HERE

20th August 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
Our parent company, Fishawack Health has reorganized to deliver agile and innovative solutions for life-sciences companies in the face of rapidly changing markets
Blue Latitude Health
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health